Skip to main content
Top

31-10-2017 | Acute myeloid leukemia | Article

Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)

Journal: Annals of Hematology

Authors: Gabriele Nagel, D. Weber, E. Fromm, S. Erhardt, M. Lübbert, W. Fiedler, T. Kindler, J. Krauter, P. Brossart, A. Kündgen, H. R. Salih, J. Westermann, G. Wulf, B. Hertenstein, M. Wattad, K. Götze, D. Kraemer, T. Heinicke, M. Girschikofsky, H.G. Derigs, H. A. Horst, C. Rudolph, M. Heuser, G. Göhring, V. Teleanu, L. Bullinger, F. Thol, V. I. Gaidzik, P. Paschka, K. Döhner, A. Ganser, Hartmut Döhner, R. F. Schlenk, German-Austrian AML Study Group (AMLSG)

Publisher: Springer Berlin Heidelberg

Abstract

We describe genetic and clinical characteristics of acute myeloid leukemia (AML) patients according to age from an academic population-based registry. Adult patients with newly diagnosed AML at 63 centers in Germany and Austria were followed within the AMLSG BiO registry (NCT01252485). Between January 1, 2012, and December 31, 2014, data of 3525 patients with AML (45% women) were collected. The median age was 65 years (range 18–94). The comparison of age-specific AML incidence rates with epidemiological cancer registries revealed excellent coverage in patients < 70 years old and good coverage up to the age of 80. The distribution according to the European LeukemiaNet (ELN) risk categorization from 2010 was 20% favorable, 31% intermediate-1, 28% intermediate-2, and 21% adverse. With increasing age, the relative but not the absolute prevalence of patients with ELN favorable and intermediate-1 risk (p < 0.001), with activating FLT3 mutations (p < 0.001), with ECOG performance status < 2 (p < 0.001), and with HCT-CI comorbidity index < 3 (p < 0.001) decreased. Regarding treatment, obesity and favorable risk were associated with an intensive treatment, whereas adverse risk, higher age, and comorbidity index > 0 were associated with non-intensive treatment or best supportive care. The AMLSG BiO registry provides reliable population-based distributions of genetic, clinical, and treatment characteristics according to age.
Literature
1.
SEER Cancer Statistics Review, 1975-2009 - Previous version—SEER Cancer Statistics Review. https://​seer.​cancer.​gov/​archive/​csr/​1975_​2009_​pops09/​. Accessed 5 Dec 2016
2.
Cancer Statistics Review, 1975–2013—SEER Statistics. https://​seer.​cancer.​gov/​csr/​1975_​2013/​. Accessed 5 Dec 2016
3.
Klepin HD, Rao AV, Pardee TS (2014) Acute myeloid leukemia and myelodysplastic syndromes in older adults. J Clin Oncol 32:2541–2552. https://​doi.​org/​10.​1200/​JCO.​2014.​55.​1564 CrossRefPubMedPubMedCentral
4.
Juliusson G, Lazarevic V, Hörstedt A-S et al (2012) Acute myeloid leukemia in the real world: why population-based registries are needed. Blood 119:3890–3899. https://​doi.​org/​10.​1182/​blood-2011-12-379008 CrossRefPubMedPubMedCentral
5.
Ocias LF, Larsen TS, Vestergaard H et al (2016) Trends in hematological cancer in the elderly in Denmark, 1980-2012. Acta Oncol 55(Suppl 1):98–107. https://​doi.​org/​10.​3109/​0284186X.​2015.​1115124 CrossRefPubMed
6.
L Bullinger, Döhner K, Döhner H (2017) Genomics of acute myeloid leukemia diagnosis and pathways. J Clin Oncol. in press
7.
Nagel G, Stocks T, Späth D et al (2012) Metabolic factors and blood cancers among 578,000 adults in the metabolic syndrome and cancer project (Me-Can). Ann Hematol 91:1519–1531. https://​doi.​org/​10.​1007/​s00277-012-1489-z CrossRefPubMed
8.
Papaemmanuil E, Gerstung M, Bullinger L et al (2016) Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 374:2209–2221. https://​doi.​org/​10.​1056/​NEJMoa1516192 CrossRefPubMedPubMedCentral
9.
Schlenk RF, Döhner H (2013) Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2013:324–330. https://​doi.​org/​10.​1182/​asheducation-2013.​1.​324 PubMed
10.
Döhner H, Weisdorf DJ, Bloomfield CD (2015) Acute myeloid leukemia. N Engl J Med 373:1136–1152. https://​doi.​org/​10.​1056/​NEJMra1406184 CrossRefPubMed
11.
Döhner H, Estey EH, Amadori S et al (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115:453–474. https://​doi.​org/​10.​1182/​blood-2009-07-235358 CrossRefPubMed
12.
Schlenk RF, Döhner K, Krauter J et al (2008) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358:1909–1918. https://​doi.​org/​10.​1056/​NEJMoa074306 CrossRefPubMed
13.
Döhner H, Estey E, Grimwade D et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129:424–447. https://​doi.​org/​10.​1182/​blood-2016-08-733196 CrossRefPubMedPubMedCentral
14.
Stone RM, Mandrekar S, Sanford BL et al (2015) The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)/cytarabine (C) induction (ind), high-dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18–60 with FLT3 mutations (muts): an international prospective randomized (rand) P-controlled double-blind trial (CALGB 10603/RATIFY [Alliance]). Blood 126:6CrossRef
15.
Gerstung M, Papaemmanuil E, Martincorena I et al (2017) Precision oncology for acute myeloid leukemia using a knowledge bank approach. Nat Genet. https://​doi.​org/​10.​1038/​ng.​3756
16.
Ostgård LSG, Nørgaard JM, Severinsen MT et al (2013) Data quality in the Danish National Acute Leukemia Registry: a hematological data resource. Clin Epidemiol 5:335–344. https://​doi.​org/​10.​2147/​CLEP.​S48411 CrossRefPubMedPubMedCentral
17.
Dinmohamed AG, Visser O, van Norden Y et al (2016) Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989-2012. Leukemia 30:24–31. https://​doi.​org/​10.​1038/​leu.​2015.​188 CrossRefPubMed
18.
Sant M, Minicozzi P, Mounier M et al (2014) Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol 15:931–942. https://​doi.​org/​10.​1016/​S1470-2045(14)70282-7 CrossRefPubMed
19.
Pulte D, Jansen L, Castro FA, Brenner H (2016) Changes in the survival of older patients with hematologic malignancies in the early 21st century. Cancer 122:2031–2040. https://​doi.​org/​10.​1002/​cncr.​30003 CrossRefPubMed
20.
Burnett A, Wetzler M, Löwenberg B (2011) Therapeutic advances in acute myeloid leukemia. J Clin Oncol 29:487–494. https://​doi.​org/​10.​1200/​JCO.​2010.​30.​1820 CrossRefPubMed
21.
Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655CrossRefPubMed
22.
Sorror ML, Maris MB, Storb R et al (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106:2912–2919. https://​doi.​org/​10.​1182/​blood-2005-05-2004 CrossRefPubMedPubMedCentral
23.
Vardiman JW, Thiele J, Arber DA et al (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937–951. https://​doi.​org/​10.​1182/​blood-2009-03-209262 CrossRefPubMed
24.
Mitelman F ISCN 1995 An international system for human cytogenetic nomenclature (1995), 1995. Karger, Basel
25.
Schlenk RF, Taskesen E, van Norden Y et al (2013) The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. Blood 122:1576–1582. https://​doi.​org/​10.​1182/​blood-2013-05-503847 CrossRefPubMed
26.
Taskesen E, Bullinger L, Corbacioglu A et al (2011) Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood 117:2469–2475. https://​doi.​org/​10.​1182/​blood-2010-09-307280 CrossRefPubMed
27.
Statistisches Bundesamt (2015) Bevölkerung 2012–2014. Statistisches Bundesamt Destatis, https://​www-genesis.​destatis.​de/​genesis/​online/​link/​tabellen/​12411*
28.
Surveillance, Epidemiology, and End Results (SEER) (2015) AML incidence 2009–2013. National cancer Institute, http://​seer.​cancer.​gov/​faststats/​selections.​php?​#Output
29.
Schneider F, Hoster E, Schneider S et al (2012) Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML). Ann Hematol 91:9–18. https://​doi.​org/​10.​1007/​s00277-011-1280-6 CrossRefPubMed
30.
Sanz MA, Iacoboni G, Montesinos P, Venditti A (2016) Emerging strategies for the treatment of older patients with acute myeloid leukemia. Ann Hematol 95:1583–1593. https://​doi.​org/​10.​1007/​s00277-016-2666-2 CrossRefPubMed
31.
Schlenk RF, Fiedler W, Salih HR et al (2016) Impact of age and midostaurin-dose on response and outcome in acute myeloid leukemia with FLT3-ITD: interim-analyses of the AMLSG 16-10 Trial. Blood 128:449CrossRef
32.
Tsai C-H, Hou H-A, Tang J-L et al (2016) Genetic alterations and their clinical implications in older patients with acute myeloid leukemia. Leukemia 30:1485–1492. https://​doi.​org/​10.​1038/​leu.​2016.​65 CrossRefPubMed
33.
Schlenk RF, Döhner K, Kneba M et al (2009) Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. Haematologica 94:54–60. https://​doi.​org/​10.​3324/​haematol.​13378 CrossRefPubMed
34.
Becker H, Marcucci G, Maharry K et al (2010) Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol 28:596–604. https://​doi.​org/​10.​1200/​JCO.​2009.​25.​1496 CrossRefPubMed
35.
Brunner AM, Sadrzadeh H, Feng Y et al (2013) Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia. Am J Hematol 88:642–646. https://​doi.​org/​10.​1002/​ajh.​23462 CrossRefPubMedPubMedCentral